Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
StemRad is a private Israeli-American medical device company that develops wearable personal radiation protection systems for healthcare workers, first responders, military personnel, nuclear-industry users, and astronauts. Its core approach is selective shielding of the body’s most radiosensitive organs, particularly bone marrow-rich pelvic structures, to reduce the risk of acute radiation syndrome and cumulative radiation injury while preserving mobility. The company markets products including 360 Gamma for high-dose gamma exposure scenarios, StemRad MD for interventional and medical staff, and AstroRad for astronaut radiation protection developed with Lockheed Martin. StemRad sits at the intersection of healthcare, defense, occupational safety, and space medicine, with a differentiated commercial focus on radiation PPE rather than therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on StemRad.